Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Net Income towards Common Stockholders (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$18.9 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 34.14% to -$18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$67.0 million through Dec 2025, down 41.73% year-over-year, with the annual reading at -$51.4 million for FY2025, 75.12% down from the prior year.
  • Net Income towards Common Stockholders hit -$18.9 million in Q4 2025 for Vistagen Therapeutics, up from -$19.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.4 million in Q4 2023 to a low of -$29.6 million in Q1 2021.
  • Historically, Net Income towards Common Stockholders has averaged -$13.6 million across 5 years, with a median of -$13.1 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 722.71% in 2021 and later surged 65.09% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$10.7 million in 2021, then rose by 9.13% to -$9.8 million in 2022, then skyrocketed by 34.95% to -$6.4 million in 2023, then crashed by 121.87% to -$14.1 million in 2024, then plummeted by 34.14% to -$18.9 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for VTGN at -$18.9 million in Q4 2025, -$19.4 million in Q3 2025, and -$15.1 million in Q2 2025.